What is Amici Pharmaceuticals?
Based in Melville, New York, Amici Pharmaceuticals operates as a specialized developer and distributor of niche generic pharmaceutical products. The company distinguishes itself through a robust network of manufacturing partners, ensuring that all finished goods adhere to rigorous good manufacturing practices. Its current product catalog spans critical therapeutic areas, including ophthalmic treatments and oral solid dosage forms. A recent milestone for the firm includes the successful market introduction of metolazone tablets, a generic alternative to Zaroxolyn, which serves patients managing edema associated with congestive heart failure and renal conditions. By prioritizing customer service and supply chain reliability, Amici Pharmaceuticals maintains a stable position in the healthcare sector, effectively bridging the gap between complex manufacturing requirements and patient access to affordable medication.
How much funding has Amici Pharmaceuticals raised?
Amici Pharmaceuticals has raised a total of $83K across 1 funding round:
Debt
$83K
Debt (2021): $83K with participation from PPP
Key Investors in Amici Pharmaceuticals
PPP
Public-Private Partnership
What's next for Amici Pharmaceuticals?
With the successful closure of this latest financing, Amici Pharmaceuticals is well-positioned to accelerate its product development pipeline and enhance its manufacturing partnerships. The company's strategic focus remains on scaling its portfolio of generic offerings, particularly in high-demand therapeutic categories. As the firm transitions through this significant growth phase, stakeholders anticipate further expansion into specialized markets, leveraging its established infrastructure to capture additional market share. The capital deployment will likely prioritize the acquisition of new product rights and the optimization of distribution channels, ensuring that Amici remains a resilient player in the evolving pharmaceutical supply chain.
See full Amici Pharmaceuticals company page
